ClinicalTrials.gg

Program

KAT2A/KAT2B Degrader AUTX-703

Its studies are mostly in Leukemia, Myeloid, Acute, led by Auron Therapeutics.

Furthest: phase 1, since Feb 6, 20251 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Auron Therapeutics11 open or runningphase 1since Feb 6, 2025Feb 6, 2025Apr 2027phase 1 · NCT06846606

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2025First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT06846606 · 69 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06846606

TargetBeta

KAT2A →KAT2B →read by rule
“An orally bioavailable, small molecule degrader of the histone acetyltransferases and transcriptional activators lysine acetyltransferase 2A (KAT2A) and its paralog lysine acetyltransferase 2B (KAT2B), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
KAT2A/B Inhibitor PF-07994525Pfizerphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06846606Leukemia, Myeloid, Acute · United States1RecruitingApr 202769

How it is read

Names in the registry

  • “AUTX-703”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.